MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma

Leukemia Research

Volumn 36, Issue 12, 2012, Pages 1505-1509

  Gao, Xiao ^a   Zhang, Run ^a   Qu, Xiaoyan ^a   Zhao, Min ^a   Zhang, Sensen ^a   Wu, Hanxin ^a   Jianyong, Li ^a   Chen, Lijuan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Del(13); MiR 15a; MiR 16 1; MiR 17 92 cluster; Multiple myeloma

Indexed keywords

MICRORNA; MICRORNA 15A; MICRORNA 16 1; MICRORNA 17 92; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHROMOSOME DELETION 13; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE CLUSTER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MULTIGENE FAMILY; MULTIPLE MYELOMA; NEOPLASM STAGING; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84868206165     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.021     Document Type: Article

References (29)

1. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64(4):1546-1558.
2. Zojer N., Konigsberg R., Ackermann J., et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000, 95(6):1925-1930.
3. Desikan R., Barlogie B., Sawyer J., et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000, 95(12):4008-4010.
4. Facon T., Avet-Loiseau H., Guillerm G., et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001, 97(6):1566-1571.
5. Fonseca R., Harrington D., Oken M.M., et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002, 62(3):715-720.
6. Herve A.L., Florence M., Philippe M., et al. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol 2011, 29(14):1893-1897.
7. Corthals S.L., Sun S.M., Kuiper R., et al. MicroRNA signatures characterize multiple myeloma patients. Leukemia 2011, 25(11):1784-1789.
8. Ronchetti D., Lionetti M., Mosca L., et al. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics 2008, 1:37.
9. Calin G.A., Ferracin M., Cimmino A., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353(17):1793-1801.
10. Calin G.A., Croce C.M. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006, 25(46):6202-6210.
11. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866.
12. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36(3):842-854.
13. Chen L., Li C., Zhang R., et al. MiR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett 2011, 309(1):62-70.
14. Chen C., Ridzon D.A., Broomer A.J., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucl Acids Res 2005, 33(20):e179.
15. Iorio M.V., Ferracin M., Liu C.G., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65(16):7065-7070.
16. Calin G.A., Liu C.G., Sevignani C., et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004, 101(32):11755-11760.
17. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358(18):1919-1928.
18. Roccaro A.M., Sacco A., Thompson B., et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009, 113(26):6669-6680.
19. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002, 99(24):15524-15529.
20. Diosdado B., de Wiel M.A.v., Terhaar S.D.J.S., et al. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 2009, 101(4):707-714.
21. Sawyer J.R. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011, 204(1):3-12.
22. Novotny G.W., Sonne S.B., Nielsen J.E., et al. Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17-92 cluster. Cell Death Differ 2007, 14(4):879-882.
23. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435(7043):839-843.
24. Ventura A., Young A.G., Winslow M.M., et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132(5):875-886.
25. Pichiorri F., Suh S.S., Ladetto M., et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008, 105(35):12885-12890.
26. Corthals S.L., Jongen-Lavrencic M., de Knegt Y., et al. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res 2010, 34(5):677-681.
27. Gutierrez N.C., Sarasquete M.E., Misiewicz-Krzeminska I., et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010, 24(3):629-637.
28. Chi J., Ballabio E., Chen X.H., et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 2011, 6:23.
29. Lionetti M., Biasiolo M., Agnelli L., et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009, 114(25):e20-e26.